3.75
price up icon7.45%   0.26
after-market Dopo l'orario di chiusura: 3.75
loading
Precedente Chiudi:
$3.49
Aprire:
$3.46
Volume 24 ore:
8.65M
Relative Volume:
1.86
Capitalizzazione di mercato:
$901.42M
Reddito:
$38.03M
Utile/perdita netta:
$-146.40M
Rapporto P/E:
-7.2115
EPS:
-0.52
Flusso di cassa netto:
$-121.38M
1 W Prestazione:
-1.32%
1M Prestazione:
+75.23%
6M Prestazione:
+23.76%
1 anno Prestazione:
+35.38%
Intervallo 1D:
Value
$3.37
$3.77
Intervallo di 1 settimana:
Value
$3.28
$3.87
Portata 52W:
Value
$1.8906
$4.085

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name
Nome
Abcellera Biologics Inc
Name
Telefono
(604) 559-9005
Name
Indirizzo
150 W 4TH AVENUE, VANCOUVER
Name
Dipendente
596
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-18
Name
Ultimi documenti SEC
Name
ABCL's Discussions on Twitter

Confronta ABCL con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ABCL
Abcellera Biologics Inc
3.75 901.42M 38.03M -146.40M -121.38M -0.52
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-08-20 Downgrade The Benchmark Company Buy → Hold
2024-02-22 Aggiornamento The Benchmark Company Hold → Buy
2023-12-05 Iniziato KeyBanc Capital Markets Overweight
2023-11-06 Downgrade The Benchmark Company Buy → Hold
2023-10-13 Ripresa Piper Sandler Overweight
2023-02-28 Iniziato Cowen Outperform
2022-12-15 Iniziato Goldman Buy
2022-11-16 Iniziato Truist Buy
2021-12-21 Iniziato The Benchmark Company Buy
2021-11-19 Iniziato Piper Sandler Overweight
2021-01-05 Iniziato BMO Capital Markets Outperform
2021-01-05 Iniziato Berenberg Buy
2021-01-05 Iniziato Credit Suisse Outperform
2021-01-05 Iniziato SVB Leerink Outperform
2021-01-05 Iniziato Stifel Buy
Mostra tutto

Abcellera Biologics Inc Borsa (ABCL) Ultime notizie

pulisher
Jun 13, 2025

AbCellera shareholders approve board election and auditor - Investing.com Australia

Jun 13, 2025
pulisher
Jun 13, 2025

AbCellera shareholders approve board election and auditor By Investing.com - Investing.com Nigeria

Jun 13, 2025
pulisher
Jun 13, 2025

AbCellera Biologics Holds Annual Shareholder Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

AbCellera Biologics: The Dilemma Of A Promising Pipeline Alongside Cash Burn (ABCL) - Seeking Alpha

Jun 13, 2025
pulisher
Jun 12, 2025

ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why - MSN

Jun 12, 2025
pulisher
Jun 11, 2025

AbCellera Biologics (ABCL) Stands Out in Active Option Classes | - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

AbCellera Biologics (ABCL) Stands Out in Active Option Classes | ABCL Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 09, 2025

AbCellera Biologics Inc. (ABCL): A Bull Case Theory - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

Squarepoint Ops LLC Acquires 44,367 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World

Jun 09, 2025
pulisher
Jun 03, 2025

AbCellera Biologics Inc. (ABCL) Approved to Begin ABCL575 Trial for Atopic Dermatitis - MSN

Jun 03, 2025
pulisher
Jun 03, 2025

AbCellera Biologics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance

Jun 03, 2025
pulisher
Jun 02, 2025

Why AbCellera Biologics Stock Raced Nearly 6% Higher Today - AOL.com

Jun 02, 2025
pulisher
Jun 02, 2025

AbCellera (ABCL) Stock Rises on Health Canada Approval - GuruFocus

Jun 02, 2025
pulisher
May 31, 2025

AbCellera gains Health Canada nod for AD antibody trial By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 30, 2025

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 - BioSpace

May 30, 2025
pulisher
May 30, 2025

AbCellera (ABCL) Gains Health Canada Approval for Clinical Trial - GuruFocus

May 30, 2025
pulisher
May 30, 2025

AbCellera Biologics Receives Health Canada Approval for Trial - TipRanks

May 30, 2025
pulisher
May 30, 2025

AbCellera Biologics Gets Health Canada Authorization for Phase 1 Trial of Dermatitis Treatment - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

AbCellera Receives Authorization from Health Canada to Initiate - GuruFocus

May 30, 2025
pulisher
May 30, 2025

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 | ABCL Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

AbCellera receives Health Canada authorization to initiate ABCL575 Phase 1 trial - TipRanks

May 30, 2025
pulisher
May 30, 2025

AbCellera gains Health Canada nod for AD antibody trial - Investing.com

May 30, 2025
pulisher
May 30, 2025

Health Canada Greenlights AbCellera's Novel Antibody Trial for Chronic Skin Disease Treatment - Stock Titan

May 30, 2025
pulisher
May 30, 2025

AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Holdings Boosted by Millennium Management LLC - Defense World

May 30, 2025
pulisher
May 30, 2025

AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential - MSN

May 30, 2025
pulisher
May 29, 2025

AbCellera Biologics Inc. raises US$100M in series A2 financing - McCarthy Tétrault

May 29, 2025
pulisher
May 20, 2025

13 Best Multibagger Stocks to Invest in Now - Insider Monkey

May 20, 2025
pulisher
May 18, 2025

Truist Financial Has Lowered Expectations for AbCellera Biologics (NASDAQ:ABCL) Stock Price - Defense World

May 18, 2025
pulisher
May 16, 2025

Truist cuts AbCellera stock target to $10, maintains Buy By Investing.com - Investing.com South Africa

May 16, 2025
pulisher
May 16, 2025

Truist Securities Lowers Price Target for AbCellera Biologics (A - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Truist cuts AbCellera stock target to $10, maintains Buy - Investing.com Australia

May 16, 2025
pulisher
May 16, 2025

Truist Securities Lowers Price Target for AbCellera Biologics (ABCL) | ABCL Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Truist Adjusts Price Target for AbCellera (ABCL) Amid Strategic Shift | ABCL Stock News - GuruFocus

May 16, 2025
pulisher
May 15, 2025

Abcellera gains Canadian clearance for phase I study of ABCL-635 for vasomotor symptoms in menopause - BioWorld MedTech

May 15, 2025
pulisher
May 15, 2025

Some Analysts Just Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Estimates - simplywall.st

May 15, 2025
pulisher
May 15, 2025

Analyst Forecasts Just Became More Bearish On AbCellera Biologics Inc. (NASDAQ:ABCL) - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

AbCellera to begin Phase 1 trial for menopause treatment By Investing.com - Investing.com Nigeria

May 15, 2025
pulisher
May 14, 2025

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause - BioSpace

May 14, 2025
pulisher
May 14, 2025

AbCellera Biologics Gets Health Canada Approval for Phase 1 Trial of Menopause Treatment - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

AbCellera to begin Phase 1 trial for menopause treatment - Investing.com

May 14, 2025
pulisher
May 14, 2025

AbCellera (ABCL) Set to Launch Clinical Trial for Menopause Trea - GuruFocus

May 14, 2025
pulisher
May 14, 2025

AbCellera (ABCL) Set to Launch Clinical Trial for Menopause Treatment | ABCL Stock News - GuruFocus

May 14, 2025

Abcellera Biologics Inc Azioni (ABCL) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):